Ultraviolet brain tumour surgery pioneered by University of Cambridge could improve accuracy of removal
Last updated 11/2/2011 10:03:47 AM
Ultraviolet brain tumour surgery pioneered by University of Cambridge could improve accuracy of removal
A new trial technique that makes brain tumours glow under ultraviolet light could enable surgeons to remove them more accurately.
Over 60 patients who have been newly diagnosed with glioblastoma, the most common and most harmful primary malignant brain tumour in adults, will take part in the trial. They have been selected because their tumours give them an average survival rate of just 15 months from diagnosis.
The surgeons will use 5-ALA (5-Amino-Levulinic Acid), which is converted in the body to a fluorescent chemical, making the tumour glow under ultraviolet light during surgery. This pioneering technique means that surgeons should be able to see the edges of the tumour more clearly, allowing more accurate and complete tumour removal.
A second therapy, given after the tumour is removed, involves inserting wafers impregnated with the chemotherapy drug carmustine into the cavity. Carmustine is then released locally to help kill remaining tumour cells.
The trial, GALA-5, is being led by Dr Colin Watts at the University of Cambridge, where the first 4 patients have been recruited. It will be rolled out to more than 10 other centres, including King's College Hospital and the National Hospital for Neurology & Neurosurgery.